Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologics comparability protocol approval could lessen manufacturing changes reporting -- CBER's Zoon.

Executive Summary

BIOLOGICS "COMPARABILITY PROTOCOL" COULD LESSEN REPORTING REQUIREMENTS, under the final rule on changes to an approved application, Center for Biologics Evaluation & Research Director Kathryn Zoon told a Food & Drug Law Institute conference on July 23. The comparability protocol "will allow the manufacturer to reduce the level of risk by putting it in a lower category based on protocol defining how you are going to do the comparison study." Zoon said that "essentially a substantial risk item moves to a moderate risk, and likewise a moderate risk might move down to an annual report-type notification, depending on its comparability protocol."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel